For patients with osteoporosis, the long-term use of bone-specific pharmacological therapies, including antiresorptive and/or osteoanabolic approaches, has raised concerns around adverse effects or potential rebound phenomena after treatment discontinuation. This Review outlines clinical data on long-term and sequential treatment for osteoporosis.
- Ines Foessl
- Hans P. Dimai
- Barbara Obermayer-Pietsch